Primer Koruma Amaçlı İmplante Edilebilir Kardiyoverter Defibrilatör
Özet
Referanslar
de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30:1500–5.
Lynge TH, Risgaard B, Banner J, et al. Nationwideburden of sudden cardiac death: a study of 54,028 deaths in Denmark. Heart Rhythm2021;18:1657–65.
Altmann DR, Mutschelknauss M, Ehl N, et al. Prevalence of severely impaired left ventricular ejection fraction after reperfused ST-elevation myocardial infarction. Swiss Med Wkly 2013;143:w13869.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.
Moss AJ, Hall WJ, Cannom DS, et al. Improved sur- vival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933–1940.
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.
Buxton AE, Lee KL, Fisher JD, et al. A rando- mized study of the prevention of sudden death in patients with coronary artery dis- ease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882–1890.
Zabel M, Willems R, Lubinski A, et al. Clinical effect- iveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020;41: 3437–3447.
Schrage B, Uijl A, Benson L, et al. Association between use of primary-prevention implantable cardioverter- defibrillators and mortality in patients with heart failure: a prospective propensity score-matched analysis from the Swedish Heart Failure Registry. Circulation 2019; 140:1530–1539.
Gatzoulis KA, Tsiachris D, Arsenos P, et al. Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study. Eur Heart J 2019;40:2940–2949.
Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a metaanalysis of randomized controlled trials. JAMA 2004;292:2874–2879.
Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375:1221–1230.
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022 Oct 21;43(40):3997-4126.
Referanslar
de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, et al. Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the maastricht area on incidence, characteristics and survival. J Am Coll Cardiol 1997; 30:1500–5.
Lynge TH, Risgaard B, Banner J, et al. Nationwideburden of sudden cardiac death: a study of 54,028 deaths in Denmark. Heart Rhythm2021;18:1657–65.
Altmann DR, Mutschelknauss M, Ehl N, et al. Prevalence of severely impaired left ventricular ejection fraction after reperfused ST-elevation myocardial infarction. Swiss Med Wkly 2013;143:w13869.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–237.
Moss AJ, Hall WJ, Cannom DS, et al. Improved sur- vival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933–1940.
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–883.
Buxton AE, Lee KL, Fisher JD, et al. A rando- mized study of the prevention of sudden death in patients with coronary artery dis- ease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882–1890.
Zabel M, Willems R, Lubinski A, et al. Clinical effect- iveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J 2020;41: 3437–3447.
Schrage B, Uijl A, Benson L, et al. Association between use of primary-prevention implantable cardioverter- defibrillators and mortality in patients with heart failure: a prospective propensity score-matched analysis from the Swedish Heart Failure Registry. Circulation 2019; 140:1530–1539.
Gatzoulis KA, Tsiachris D, Arsenos P, et al. Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study. Eur Heart J 2019;40:2940–2949.
Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a metaanalysis of randomized controlled trials. JAMA 2004;292:2874–2879.
Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375:1221–1230.
Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022 Oct 21;43(40):3997-4126.
